BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24609758)

  • 1. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort.
    Nikiphorou E; Negoescu A; Fitzpatrick JD; Goudie CT; Badcock A; Östör AJ; Malaviya AP
    Clin Rheumatol; 2014 May; 33(5):609-14. PubMed ID: 24609758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD; Baker JF; Ogdie A
    J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.
    Behrens F; Koehm M; Schwaneck EC; Schmalzing M; Wittig BM; Gnann H; Greger G; Tony HP; Burkhardt H
    Scand J Rheumatol; 2019 Sep; 48(5):375-382. PubMed ID: 31311386
    [No Abstract]   [Full Text] [Related]  

  • 5. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
    Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
    Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature.
    Salaffi F; Manganelli P; Carotti M; Subiaco S; Lamanna G; Cervini C
    Clin Rheumatol; 1997 May; 16(3):296-304. PubMed ID: 9184269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis.
    Dalkilic E; Sahbazlar M; Gullulu M; Yavuz M; Dilek K; Ersoy A; Ozkaya G; Yurtkuran M
    Mod Rheumatol; 2013 May; 23(3):525-8. PubMed ID: 22752502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of low dose methotrexate on bone density.
    Cranney AB; McKendry RJ; Wells GA; Ooi DS; Kanigsberg ND; Kraag GR; Smith CD
    J Rheumatol; 2001 Nov; 28(11):2395-9. PubMed ID: 11708409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I; Koó E; Seszták M; Gergely P
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
    Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
    Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis.
    Ćalasan MB; van den Bosch OF; Creemers MC; Custers M; Heurkens AH; van Woerkom JM; Wulffraat NM
    Arthritis Res Ther; 2013; 15(6):R217. PubMed ID: 24345416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?
    Pincus T; Bergman MJ; Yazici Y
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S82-93. PubMed ID: 26472658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study.
    Seitz M; Reichenbach S; Möller B; Zwahlen M; Villiger PM; Dufour JF
    Ann Rheum Dis; 2010 Jun; 69(6):1148-50. PubMed ID: 19854710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS; Taylor WJ;
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
    Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
    Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.